444 related articles for article (PubMed ID: 34156647)
1. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.
Sridharan K; Abbasi MY; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
Giachetto GA; Telechea HM; Speranza N; Oyarzun M; Nanni L; Menchaca A
Pediatr Crit Care Med; 2011 Nov; 12(6):e250-4. PubMed ID: 21057350
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics of Vancomycin in Critically Ill Children.
Sridharan K; Al Daylami A; Ajjawi R; Al-Ajooz H; Veeramuthu S
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):807-816. PubMed ID: 31301023
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy.
Economou CJP; Kielstein JT; Czock D; Xie J; Field J; Richards B; Tallott M; Visser A; Koenig C; Hafer C; Schmidt JJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2018 Aug; 52(2):151-157. PubMed ID: 29526606
[TBL] [Abstract][Full Text] [Related]
6. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
[TBL] [Abstract][Full Text] [Related]
7. Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children.
Genuini M; Oualha M; Bouazza N; Moulin F; Treluyer JM; Lesage F; Renolleau S; Benaboud S
Pediatr Crit Care Med; 2018 Jun; 19(6):e263-e269. PubMed ID: 29394210
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
[TBL] [Abstract][Full Text] [Related]
11. The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients.
Chen J; Huang X; Bu S; Chen X; Zhou J; Liu X; Guo X; Li L; Zhang J
Pharmacol Res Perspect; 2021 Dec; 9(6):e00885. PubMed ID: 34664790
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Clin Pharmacokinet; 2020 Mar; 59(3):327-334. PubMed ID: 31471789
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin is commonly under-dosed in critically ill children and neonates.
Sosnin N; Curtis N; Cranswick N; Chiletti R; Gwee A
Br J Clin Pharmacol; 2019 Nov; 85(11):2591-2598. PubMed ID: 31378957
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
16. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients.
Shoji K; Saito J; Nakagawa H; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Momper JD; Capparelli EV; Miyairi I
Microbiol Spectr; 2021 Oct; 9(2):e0046021. PubMed ID: 34612690
[TBL] [Abstract][Full Text] [Related]
20. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
